Industry Relations Updates
Industry Relations UpdatesAmerican Epilepsy Society Annual Meeting, Chicago 12/2022 Longboard Pharmaceuticals plans to initiate a phase 1b/2a* clinical study for their
It Takes a Village
After Eliana was born, we spent five months in the NICU of our local children’s hospital. I quickly realized how
Expanded Access Programs, What you Need to Know
Expanded Access Program May Offer Drug Access to SCN2A Kiddos Prior to a Potential Drug Approval – Praxis has disclosed that
Why I Study SCN2A
I’m a neuroscience postdoctoral researcher in the lab of Loren Frank at UCSF. I’m fascinated by Scn2a because I want
Decisions, Decisions, Decisions.
As a parent of a non-verbal, non-ambulatory child I am forced to make decisions for her on a daily basis—what
Praxis Precision Medicines, Inc updated our SCN2A community on the status of their three SCN2A programs in development and their CIITIZEN partnership.
PRAX-562 PRAX-562 is currently in phase 1 clinical trials (meaning it is being tested in humans). This agent has completed
FINDING YOUR VOICE
FINDING MY VOICE On a cold January morning during the first week of what, unbeknownst to me, would become a